How can we identify those 2 year survivors winners?
Nivolumab vs Docetaxel
CheckMate 017 Phase III
Nivolumab vs Docetaxel
CheckMate 057 Phase III
Pembrolizumb vs Docetaxel
KeyNote 010 Phase III
Atezolizumab vs Docetaxel
Poplar
Phase II
Atezoliuzmab vs Docetaxel
OAK Phase III
Line of T
2nd 100%
2nd line 100%
2nd line 65%, 3rd line 35%
2nd 70% 3rd 20%m > 3 10%
2nd l75% 3rd 25%
ORR
20% vs 9%
19% vs 12%
18% vs 18%
15% vs 15%
14 vs 13%
PFS m
3.5 vs 2.8
2.3 vs 4.2
3.9 vs 4 vs 4
2.7 vs 3
2.8 vs 4
OS m
9.2 vs 6
12.2 vs 9.4m
10.4-12.7 vs 8.5
12.7 vs 9.7
10.1 vs 8.6 (SCC)
13.8 vs 9.6
HR OS
HR PDL1-
HR PDL1+
0.59
0.70
0.50
0.73
0.87
0.40
0.71-0.61
NA
0.54-0.50
0.73
1.09
0.49
0.73
0.75
0.41
